Crowd sentiment on PHGE · 30d

Method · 0 mentions

Bullish 0%

Neutral 100%

Bearish 0%

Across 0 classified mentions in the last 30 days, crowd sentiment for PHGE sits roughly neutral, with 0% reading bullish against 0% bearish across the classified sample.

PHGE earnings

SEC EDGAR

Date Period EPS Revenue

31 Mar 2026 Q1 2026 $7.38 —

31 Dec 2025 FY 2025 $22.19 —

30 Sep 2025 Q3 2025 $0.29 —

30 Jun 2025 Q2 2025 $0.19 —

Reported figures & scheduled dates · SEC EDGAR filings

About PHGE

Biomx is a clinical-stage company that develops products using natural and engineered bacteriophage technologies to target specific harmful bacteria associated with chronic diseases. The company offers two types of phage-based therapies: fixed cocktail therapy and personalized therapy, both developed using its proprietary research and development platform. In December 2025, Biomx discontinued development of its BX004 product for Cystic Fibrosis and its Israeli subsidiary began insolvency proceedings, resulting in significant operational impacts and workforce reductions.

Company

CEO Mr. Michael Oster

Founded 2005

Employees 20

Headquarters Dover, DE, United States

Exchange NYSE American

Sector Industrials

Class Equity

Mentions · 30d 0

Classified base n=0

Website biomx.com

Most-discussed this week

GOOGL Alphabet MSFT Microsoft NFLX Netflix NVDA NVIDIA